pharmaceutical investing Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
pharmaceutical investing Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm Sublingual Film
pharmaceutical investing Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
pharmaceutical investing Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
pharmaceutical investing Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm Sublingual Film
pharmaceutical investing Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
pharmaceutical investing Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
pharmaceutical investing Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
pharmaceutical investing Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
pharmaceutical investing Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm Sublingual Film
pharmaceutical investing Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
pharmaceutical investing Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635
pharmaceutical investing Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
pharmaceutical investing Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
Sankamap Expands Exploration Footprint at Fauro as Systematic Prospecting Advances and New Gold Targets Emerge
NevGold Defines Multiple High-Priority Drill Targets Including Key Feeder Structures at Nutmeg Mountain Gold Project, Idaho
Brixton Drills 58 m of 0.50 g/t AuEq and 17.6 m of 1.47 g/t AuEq in the Glenfiddich Zone at Camp Creek, Thorn Project
SAGA Metals Advances Radar Project to Stage 2 RCL Optimization Targeting First High-Purity Titanium, Vanadium and Iron Products
